Physician profile
James E Siegler
NPI 1104265529
$48,769.27
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $12K · 2021: $12K · 2022: $6,457 · 2023: $220 · 2024: $4,942 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,241.50 |
| Food and Beverage | $848.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $19,804.00 | 2020-2025 | Pocket Eeg Device |
| Astrazeneca Pharmaceuticals LP | $13,859.46 | 2021-2024 | Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $6,864.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $4,607.95 | 2024-2025 | |
| Btg International INC. | $1,680.00 | 2025 | |
| Viz.Ai, INC. | $505.89 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $248.39 | 2020-2021 | |
| Imperative Care, INC | $193.71 | 2022 | |
| Chiesi USA, INC. | $153.68 | 2023-2025 | Cleviprex, Kengreal |
| Genentech USA, INC. | $147.06 | 2019-2025 | Tnkase |
| Portola Pharmaceuticals, LLC | $134.86 | 2020 | |
| Sk Life Science, INC. | $68.92 | 2021-2022 | |
| Balt USA, LLC | $65.57 | 2025 | Optima Coil System |
| Alexion Pharmaceuticals, INC. | $57.69 | 2020 | |
| Ucb, INC. | $57.56 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $45.92 | 2022 | |
| Eisai INC. | $45.60 | 2021-2022 | |
| Philips North America LLC | $44.55 | 2022-2023 | |
| Boston Scientific Corporation | $32.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.38 | 2021 | |
| Lilly USA, LLC | $25.20 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $24.46 | 2022 | |
| Greenwich Biosciences, INC. | $16.97 | 2019 | |
| Biogen, INC. | $15.22 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.93 | 2021 | |
| Medtronic, INC. | $14.74 | 2023 | Linq II |
| Neurelis, INC. | $13.83 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Siegler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.